USPTO serial 97325930
Reviewed by CopyMark Law Group
This page summarizes the public USPTO record for this serial number, including owners, goods and services, and prosecution history.
If you own this trademark, we can monitor new filings and help with USPTO deadlines. If you do not, we can file a new U.S. application.
The USPTO lists this attorney as the applicant's representative for correspondence on this application.
EMILIA F. CANNELLA
EMILIA F. CANNELLA ROPES & GRAY LLP800 BOYLSTON STREETPRUDENTIAL TOWERBOSTON, MA 02199| Class | Description | Status | First use |
|---|---|---|---|
| 005 | Pharmaceutical products and preparations for central nervous system and ophthalmic diseases and disorders; genetic therapy products and preparations, namely, oligonucleotide therapies for central nervous system and ophthalmic diseases and disorders; biological products and preparations, namely, monoclonal antibodies, multi-specific antibodies, protein therapeutics, and cell-based therapeutics for central nervous system and ophthalmic diseases and disorders for medical use; all of the foregoing excluding dietary and nutritional supplements | ACTIVE | — |
| 042 | Scientific research and development; research and development in the pharmaceutical and biotechnology fields; research and development of technology in the fields of disease treatment and gene therapy; technological assessment, research, and development of medical devices, pharmaceutical products, gene therapies, and treatment modalities for a range of diseases | ACTIVE | — |
CopyMark links this record to cited §2(d) serials, the owner's other marks, Nice classes, similar mark names, and recently changed USPTO applications.
| Date | Code | Event | What it means |
|---|---|---|---|
| Mar 30, 2026 | MAB6 | ABANDONMENT NOTICE E-MAILED - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Mar 30, 2026 | ABN6 | ABANDONMENT - NO USE STATEMENT FILED | The intent-to-use application was abandoned because no acceptable Statement of Use (or valid extension) was filed before the Notice of Allowance deadline expired. The application is dead unless revived within a limited window. |
| Jul 23, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jul 22, 2025 | EX4G | SOU EXTENSION 4 GRANTED | — |
| Jul 22, 2025 | EXT4 | SOU EXTENSION 4 FILED | — |
| Jul 22, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 21, 2025 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 20, 2025 | EX3G | SOU EXTENSION 3 GRANTED | — |
| Feb 20, 2025 | EXT3 | SOU EXTENSION 3 FILED | — |
| Feb 20, 2025 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Jun 12, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Jun 12, 2024 | EX2G | SOU EXTENSION 2 GRANTED | — |
| Jun 12, 2024 | EXT2 | SOU EXTENSION 2 FILED | — |
| Jun 12, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Feb 9, 2024 | EXRA | NOTICE OF APPROVAL OF EXTENSION REQUEST E-MAILED | — |
| Feb 8, 2024 | EX1G | SOU EXTENSION 1 GRANTED | — |
| Feb 8, 2024 | EXT1 | SOU EXTENSION 1 FILED | — |
| Feb 8, 2024 | EEXT | SOU TEAS EXTENSION RECEIVED | The applicant requested more time to file a Statement of Use before the Notice of Allowance deadline. Each extension typically adds six months. A limited number of extensions are available for intent-to-use applications not yet in use. |
| Aug 22, 2023 | NOAM | NOA E-MAILED - SOU REQUIRED FROM APPLICANT | A Notice of Allowance means your intent-to-use application cleared examination and opposition but is not registered yet. You must file a Statement of Use showing the mark in commerce, or request an extension, before the deadline — usually six months from the notice date. |
| Jul 7, 2023 | TMBN | TTAB RELEASE CASE TO TRADEMARKS | — |
| Jul 7, 2023 | OP.T | OPPOSITION TERMINATED NO. 999999 | — |
| Jul 7, 2023 | OP.D | OPPOSITION DISMISSED NO. 999999 | — |
| Feb 1, 2023 | OP.I | OPPOSITION INSTITUTED NO. 999999 | — |
| Feb 1, 2023 | OPPF | OPPOSITION PAPERS RECEIVED AT TTAB | — |
| Jan 24, 2023 | NPUB | OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED | — |
| Jan 24, 2023 | PUBO | PUBLISHED FOR OPPOSITION | Your mark was published in the USPTO Official Gazette for a 30-day opposition window. During that period, third parties who believe they would be harmed can file an opposition. If no opposition is filed, prosecution usually continues toward registration or a Notice of Allowance. |
| Jan 4, 2023 | NONP | NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED | — |
| Dec 20, 2022 | CNSA | APPROVED FOR PUB - PRINCIPAL REGISTER | — |
| Nov 22, 2022 | TEME | TEAS/EMAIL CORRESPONDENCE ENTERED | — |
| Nov 22, 2022 | CRFA | CORRESPONDENCE RECEIVED IN LAW OFFICE | — |
| Nov 22, 2022 | TROA | TEAS RESPONSE TO OFFICE ACTION RECEIVED | This event means the applicant filed a response to a USPTO Office Action — typically arguments, amendments, or evidence addressing the examiner's objections. The USPTO will review the response and either allow the mark to proceed or issue another action. |
| May 27, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | GNRN | NOTIFICATION OF NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | GNRT | NON-FINAL ACTION E-MAILED | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | CNRT | NON-FINAL ACTION WRITTEN | A non-final Office Action means the USPTO examining attorney has raised at least one issue with your trademark application but has not made a final decision. You usually have three months to respond with arguments, amendments, or evidence. Missing the deadline can abandon the application. |
| May 27, 2022 | DOCK | ASSIGNED TO EXAMINER | — |
| Mar 28, 2022 | NWOS | NEW APPLICATION OFFICE SUPPLIED DATA ENTERED | — |
| Mar 26, 2022 | NWAP | NEW APPLICATION ENTERED | — |